Home > Report Information
The Worldwide Influenza Market
BCC Research
May 30, 2006 139 Pages - SKU: WA1308163
|
|
Countries covered: Global
REPORT HIGHLIGHTS
- By 2010, the worldwide influenza market is likely to reach $7.1 billion, with average annual growth estimated at 19.8%.
- The worldwide influenza market is estimated at $2.9 billion in 2005, up from $1.5 billion the previous year.
- The market is estimated to reach $7.1 billion in 2010, an increase of more than $4.2 billion over the forecast period.
- The worldwide therapeutics/vaccines market is likely to reach $6.9 billion in 2010, with average annual growth estimated at 20.8%.
INTRODUCTION
Annually, more than 3.5 million people die of influenza, and with the threat of a pandemic government agencies and disease prevention organizations are devoted to gain control of the situation. Many companies have been asked to assist with the problem and others are furthering their position with backing from government agencies. The next year will continue to display support and funding for many research and development programs, product development and pandemic prevention and/or control.
This new report from BCC Research is designed to be a helpful business tool that will provide thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics. The geographic scope of this study is worldwide, with emphasis on U.S. data. The report identifies markets in general segments: Vaccines/ Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, use of products, forecasts, and competitive analysis. Additionally, the study covers some of most significant issues and trends and market factors.
SCOPE OF STUDY
This report:
- Provides a thorough evaluation of the market for influenza vaccines, therapeutics, and diagnostics.
- Offers a global analysis, with emphasis on U.S. data, and a five-year forecast period through 2010.
- Identifies markets in general segments: Vaccines/Therapeutics and Diagnostics. Each market segment discussion provides detailed information based on product categories, use of products, forecasts, and competitive analysis.
- Covers some of the most significant issues, trends and market factors.
- Profiles the top companies and major players in the market.
METHODOLOGY
The information for this BCC Research report was obtained through primary and secondary data-collection methods. Primary methods included interviews with key representatives in the industry: product development managers, clinical specialists, government departments, and other key representatives involved in the influenza industry. Secondary methods included published literature, investment reports, company literature, and various business journals that have emphasis on influenza products, technology and related information.
Market data for this report pertains to the worldwide market, with U.S. data included. All information is displayed using U.S. dollars at the manufacturers' level. The base year of the report is 2005, with historical data provided for 2003 and 2004, and forecast data provided through 2010. Historical, base year, and forecast data are provided for each market segment of the report. Average annual growth rates are determined through a complication of data, including past trends, future trends, demographics, incidence, mortality, products in research and development, current product growth, and government intervention and stockpiling trends. Competitor market share estimates are provided for each market segment for the 2005 base year.
|
- INTRODUCTION
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THE STUDY
- SCOPE AND FORMAT
- METHODOLOGY
- RELATED BCC STUDIES
- ANALYST CREDENTIALS
- BCC ONLINE SERVICES
- DISCLAIMER
- SUMMARY
- THE INFLUENZA MARKET: MAJOR MARKETS
- SUMMARY TABLE GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, THROUGH 2010 ($ MILLION)
- SUMMARY FIGURE WORLDWIDE INFLUENZA MARKET ANALYSIS BY PRODUCT SEGMENT, 2003-2010 ($ MILLIONS)
- INDUSTRY OVERVIEW
- TABLE 1 VACCINE RECOMMENDATIONS
- HISTORY OF THE MARKET
- EPIDEMICS/PANDEMICS
- Spanish Influenza 1918-1919
- Hong Kong Influenza 1968
- Russian Influenza 1977
- Asian Influenza 1957
- Swine Flu 1976
- Avian Flu 1961, 1997, 2003-Present
- Virus Mutations
- Types of Influenza
- Influenza Type A
- Influenza A H5
- Influenza A H7
- Influenza A H9
- Influenza Type B
- Influenza Type C
- TABLE 2 WORLDWIDE INFLUENZA ACTIVITY
- VIRAL SURVEILLANCE
- TABLE 3 VIRAL SURVEILLANCE, PERCENTAGE OF INFLUENZA VIRUS TYPE, 2004-2005 AND 2005-2006 FLU SEASONS (%)
- CURRENT H5N1 VIRUS “DRIFT AND SHIFT”
- DEVELOPMENT OF FLU VACCINES
- TABLE 4 INFLUENZA RESEARCH TEAMS AND AREAS OF STUDY
- WORLD DEMOGRAPHICS AND INCIDENCE/MORTALITY
- TABLE 5 ESTIMATED GLOBAL POPULATION BY SELECTED AGE GROUP, 2003-2010 (MILLIONS)
- FIGURE 1 ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP, 2003-2010 (MILLIONS)
- TABLE 6 ESTIMATED WORLD POPULATION INCLUDING SOME COUNTRIES, 2003-2010 (MILLIONS)
- FIGURE 2 ESTIMATED WORLD POPULATION BY REGION, 2003- 2010 (MILLIONS)
- TABLE 7 WORLDWIDE VIRAL STATISTICS, 2005
- TABLE 8 UNITED STATES VIRAL STATISTICS, 2005
- ISSUES AFFECTING THE MARKET
- GOVERNMENT INTERVENTION
- UNITED STATES
- TABLE 9 COUNTRIES WITH US EMBARGOES FOR BIRDS
- Chinese and United States Governments
- Turkey and the United States
- WHO and CDC
- WHO
- TABLE 10 WHO REPORTED CASES OF AVIAN FLU IN HUMANS, MARCH 2006
- The WHO and Containment Issues
- TABLE 11 APPROVED WHO INFLUENZA CENTERS BY REGION
- CDC
- TABLE 12 CONFIRMED CASES OF AVIAN FLU OUTBREAKS IN ANIMALS WORLDWIDE, 2003 TO PRESENT
- LEGISLATION
- Department of Defense, Emergency Supplemental Appropriations to Address Hurricanes in The Gulf OF Mexico
- Global Network for Avian Influenza Surveillance Act
- Pandemic Preparedness and Response Act
- Pandemic and Seasonal Influenza Act Of 2005
- Seasonal Influenza and Pandemic Preparation Act of 2005
- National Biodefense and Pandemic Preparedness Act of 2005
- EPIDEMIC/PANDEMIC PREPAREDNESS
- TABLE 13 ALLOCATED FUNDS FOR INFLUENZA RESEARCH AND DEVELOPMENT
- IMMATERIALIZED MARKET RISK
- VACCINE STOCKPILES
- MEDIA COVERAGE AND VACCINATIONS
- EPIDEMIC/PANDEMIC THREAT
- TABLE 14 ESTIMATED INCIDENCE OF INFLUENZA IN SEVERE OUTBREAKS BASED ON POPULATION ESTIMATES, US CENSUS BUREAU INTERNATIONAL DATABASE
- TABLE 15 PREDICTED IMPACT ON HEALTH SERVICES FROM THE
- NEXT INFLUENZA PANDEMIC IN THE TROPICS, BASED ON CDC’S FLUAID PREDICTION MODEL FOR PEAK WEEK
- TECHNOLOGY
- CURRENT USES OF TECHNOLOGY
- CDC TESTING KIT
- BD MEDICAL AND GLA
- PATENT ANALYSIS
- TABLE 16 US PATENT EVALUATION FOR MAJOR TECHNOLOGY
- BY ISSUE DATE
- TABLE 17 US PATENT EVALUATION FOR MAJOR INFLUENZA MARKET COMPETITORS, BY PATENT HOLDER AND NUMBER OF PATENTS
- FIGURE 3 US PATENT EVALUATION FOR MAJOR INFLUENZA TECHNOLOGY PATENT HOLDERS, BY PERCENT (%)
- EMERGING AREAS OF TECHNOLOGY
- Stmicroelectronics and Veredus Laboratories
- Sanofi Pasteur and BD Biosciences
- NASAL POWDER VACCINE
- INFLUENZA THERAPIES/VACCINES
- OVERVIEW
- PRODUCT DESCRIPTIONS
- TABLE 18 MARKETED FLU VIRUS PRODUCTS, THROUGH 2005
- TABLE 19 GENERIC AVAILABILITY
- TABLE 20 VACCINE AVERAGE PRICE PER UNIT DOSE, 2005-
- INFLUENZA SEASON
- RESEARCH AND DEVELOPMENT
- TABLE 21 RESEARCH AND DEVELOPMENT EFFORTS BY STATUS
- MARKET ANALYSIS
- TABLE 22 GLOBAL FORECAST FOR INFLUENZA THERAPEUTIC AND VACCINE REVENUES BY MARKET, THROUGH 2010 ($ MILLIONS)
- FIGURE 4 GLOBAL FORECAST FOR INFLUENZA THERAPEUTICS AND VACCINES BY REGION, 2003-2010 ($ MILLIONS)
- TABLE 23 GLOBAL FORECAST FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, THROUGH 2010 ($ MILLIONSA
- FIGURE 5 REVENUES FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT TYPE, 2003-2010 ($ MILLIONS)
- TABLE 24 UNITS FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT, 2005-2006 SEASON (MILLION UNITS)
- FIGURE 6 SHARE OF UNITS FOR INFLUENZA THERAPEUTICS AND VACCINES BY PRODUCT, 2005-2006 SEASON (%)
- LEADING SUPPLIERS AND PARTICIPANTS
- TABLE 25 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, 2005 (%)
- FIGURE 7 LEADING PARTICIPANTS FOR INFLUENZA THERAPEUTICS/VACCINES BY PERCENT, 2005 (%)
- INFLUENZA DIAGNOSTICS
- OVERVIEW
- TABLE 26 INFLUENZA DIAGNOSTIC TABLE
- PRODUCT DESCRIPTIONS
- CONVENTIONAL LABORATORY TESTS
- RAPID TESTING
- TABLE 27 MARKETED PRODUCTS, THROUGH 2005
- TABLE 28 RAPID INFLUENZA TESTS AVERAGE PRICE
- LABORATORY TEST SERVICES
- TABLE 29 PROVIDERS OF LABORATORY TEST SERVICES
- MARKET ANALYSIS
- TABLE 30 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, THROUGH 2010 ($ MILLIONS)
- FIGURE 8 REVENUES FOR INFLUENZA DIAGNOSTICS BY MARKET, 2003-2010 ($ MILLIONS)
- TABLE 31 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, THROUGH 2010 ($ MILLIONS)
- FIGURE 9 REVENUES FOR INFLUENZA DIAGNOSTICS BY PRODUCT TYPE, 2003-2010 ($ MILLIONS)
- TABLE 32 GLOBAL FORECAST OF INFLUENZA DIAGNOSTICS SERVICE REVENUES, THROUGH 2010 ($ MILLIONS)
- FIGURE 10 REVENUES FOR INFLUENZA DIAGNOSTICS SERVICES, 2003-2010 ($ MILLIONS)
- TABLE 33 GLOBAL FORECAST OF INFLUENZA DIAGNOSTIC PRODUCT AND SERVICES MARKET REVENUES, THROUGH ($ MILLION)
- FIGURE 11 GLOBAL INFLUENZA DIAGNOSTIC PRODUCT AND SERVICES MARKET REVENUES, 2003-2010 ($ MILLION)
- LEADING SUPPLIERS AND PARTICIPANTS
- TABLE 34 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENT, 2005 (%)
- FIGURE 12 LEADING PARTICIPANTS FOR INFLUENZA DIAGNOSTICS BY PERCENT, 2005 (%)
- MARKET SUMMARY
- TOTAL MARKET ANALYSIS
- TABLE 35 GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, THROUGH 2010 ($ MILLION)
- FIGURE 13 GLOBAL FORECAST OF THE INFLUENZA MARKET BY PRODUCT SEGMENT, 2003-2010 ($ MILLION)
- INDUSTRY PARTICIPANTS
- TABLE 36 MAJOR INDUSTRY PARTICIPANTS BY PRODUCT SEGMENT
- COMPANY PROFILES
- ACAMBIS
- ALPHAVA
- ALNYLAM PHARMACEUTICALS
- APPLIED BIOSYSTEMS
- AVI BIOPHARMA
- BECTON-DICKINSON
- BIOCRYST PHARMACEUTICALS, INC
- BIOTA HOLDINGS LTD
- CHIRON CORP
- ENDO PHARMACEUTICALS HOLDINGS INC
- FOREST LABORATORIES, INC
- GLA
- HEMISPHER
- INVERNESS MEDICAL-BIOSTAR, INC
- MEDIMMUNE VACCINES, INC
- OTSUKA PHARMACEUTICAL CO, LTD
- PATHOLOGY ASSOCIATES MEDICAL LABORATORIES (PAML)
- QUEST DIAGNOSTICS
- QUIDEL CORP
- REMEL, INC
- ROCHE HOLDINGS LTD
- SANOFI PASTEUR
- SOLVAY PHARMACEUTICALS, INC
- SYSME
- TEVA PHARMACEUTICALS INDUSTRIES LTD
- VIROMED LABORATORIES, INC
- ZYMET
- APPENDIX
- FIGURE 14 COMPANIES MENTIONED IN THE MARKET FOR
- INFLUENZA TREATMENTS AND DIAGNOSTICS, BY TYPE (NUMBER OF COMPANIES)
- LEADING PRODUCT PROVIDERS
- RESEARCH AND DEVELOPMENT AND AFFILIATED COMPANIES
- MENTIONED UNIVERSITIES
More Global Respiratory/Pulmonary Reports
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 by
GlobalData
Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Viral Respiratory Tract Infection Global Clinical Trials Review, H1, 2012 provides data ...
Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2012 by
GlobalData
Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Obstructive Pulmonary Disease Global Clinical Trials Review, H1, 2012 provides data on the ...
Lung Injury Global Clinical Trials Review, H1, 2012 by
GlobalData
Lung Injury Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Lung Injury Global Clinical Trials Review, H1, 2012 provides data on the Lung Injury ...
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 by
GlobalData
Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Bronchopulmonary Dysplasia Global Clinical Trials Review, H1, 2012 provides data on the Bronchopulmonary Dysplasia ...
Bronchospasm Global Clinical Trials Review, H1, 2012 by
GlobalData
Bronchospasm Global Clinical Trials Review, H1, 2012 Summary GlobalData's clinical trial report, “Bronchospasm Global Clinical Trials Review, H1, 2012 provides data on the Bronchospasm clinical trial scenario. ...
See all reports like this >>
Share this report
Other tasks Related Markets Respiratory/Pulmonary Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
